Strategies for Preventing Endoscopic Recurrence of Crohn’s Disease 1 Year after Surgery: A Network Meta-Analysis
Objective. To assess the benefits of different treatments that aim to prevent the endoscopic recurrence of Crohn’s disease (CD) after ileal resection. Methods. Randomized controlled trials (RCTs) were searched from MEDLINE, Embase, and the Cochrane Central Database. All the included RCTs with an end...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2017/7896160 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850169544080883712 |
|---|---|
| author | Jin-shan Feng Jin-yu Li Xiu-yan Chen Zheng Yang Shang-hai Li |
| author_facet | Jin-shan Feng Jin-yu Li Xiu-yan Chen Zheng Yang Shang-hai Li |
| author_sort | Jin-shan Feng |
| collection | DOAJ |
| description | Objective. To assess the benefits of different treatments that aim to prevent the endoscopic recurrence of Crohn’s disease (CD) after ileal resection. Methods. Randomized controlled trials (RCTs) were searched from MEDLINE, Embase, and the Cochrane Central Database. All the included RCTs with an endoscopic recurrence outcome which was defined as Rutgeerts’ score ≥ i2 have a duration of more than 1 year. The quality of the included RCTs was assessed by the Cochrane Risk of Bias Tool. Pairwise treatment effects were estimated through a Bayesian random effects network meta-analysis by using the OpenBUGS 1.4 software and reported as odds ratios (ORs) with a 95% credible interval (CI). Results. Fourteen RCTs (877 participants) were included. Two strategies were superior to placebo for preventing endoscopic recurrence of CD at 1 year after surgery: infliximab (d, −5.475; 95% CI, −10.47 to –1.632) and adalimumab (d, −7.273; 95% CI, −13.84 to −2.585). Nine strategies were not effective: budesnoid, mesalazine (in both high and low dose), azathioprine, Tripterygium wilfordii, mesalazine + infliximab, ornidazole, untreated intervention, and Lactobacillus GG. Conclusions. Except for infliximab and adalimumab, other strategies included in our analysis were not effective for preventing endoscopic recurrence of CD at 1 year after ileal resection. |
| format | Article |
| id | doaj-art-aa35d7692a72407f9a331f3b6ca13af7 |
| institution | OA Journals |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-aa35d7692a72407f9a331f3b6ca13af72025-08-20T02:20:41ZengWileyGastroenterology Research and Practice1687-61211687-630X2017-01-01201710.1155/2017/78961607896160Strategies for Preventing Endoscopic Recurrence of Crohn’s Disease 1 Year after Surgery: A Network Meta-AnalysisJin-shan Feng0Jin-yu Li1Xiu-yan Chen2Zheng Yang3Shang-hai Li4College of Pharmacy, Guangdong Medical University, Zhanjiang 524023, ChinaFirst School of Clinical Medicine, Guangdong Medical University, Zhanjiang 524023, ChinaFirst School of Clinical Medicine, Guangdong Medical University, Zhanjiang 524023, ChinaDepartment of Psychology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524023, ChinaDepartment of Cardiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524023, ChinaObjective. To assess the benefits of different treatments that aim to prevent the endoscopic recurrence of Crohn’s disease (CD) after ileal resection. Methods. Randomized controlled trials (RCTs) were searched from MEDLINE, Embase, and the Cochrane Central Database. All the included RCTs with an endoscopic recurrence outcome which was defined as Rutgeerts’ score ≥ i2 have a duration of more than 1 year. The quality of the included RCTs was assessed by the Cochrane Risk of Bias Tool. Pairwise treatment effects were estimated through a Bayesian random effects network meta-analysis by using the OpenBUGS 1.4 software and reported as odds ratios (ORs) with a 95% credible interval (CI). Results. Fourteen RCTs (877 participants) were included. Two strategies were superior to placebo for preventing endoscopic recurrence of CD at 1 year after surgery: infliximab (d, −5.475; 95% CI, −10.47 to –1.632) and adalimumab (d, −7.273; 95% CI, −13.84 to −2.585). Nine strategies were not effective: budesnoid, mesalazine (in both high and low dose), azathioprine, Tripterygium wilfordii, mesalazine + infliximab, ornidazole, untreated intervention, and Lactobacillus GG. Conclusions. Except for infliximab and adalimumab, other strategies included in our analysis were not effective for preventing endoscopic recurrence of CD at 1 year after ileal resection.http://dx.doi.org/10.1155/2017/7896160 |
| spellingShingle | Jin-shan Feng Jin-yu Li Xiu-yan Chen Zheng Yang Shang-hai Li Strategies for Preventing Endoscopic Recurrence of Crohn’s Disease 1 Year after Surgery: A Network Meta-Analysis Gastroenterology Research and Practice |
| title | Strategies for Preventing Endoscopic Recurrence of Crohn’s Disease 1 Year after Surgery: A Network Meta-Analysis |
| title_full | Strategies for Preventing Endoscopic Recurrence of Crohn’s Disease 1 Year after Surgery: A Network Meta-Analysis |
| title_fullStr | Strategies for Preventing Endoscopic Recurrence of Crohn’s Disease 1 Year after Surgery: A Network Meta-Analysis |
| title_full_unstemmed | Strategies for Preventing Endoscopic Recurrence of Crohn’s Disease 1 Year after Surgery: A Network Meta-Analysis |
| title_short | Strategies for Preventing Endoscopic Recurrence of Crohn’s Disease 1 Year after Surgery: A Network Meta-Analysis |
| title_sort | strategies for preventing endoscopic recurrence of crohn s disease 1 year after surgery a network meta analysis |
| url | http://dx.doi.org/10.1155/2017/7896160 |
| work_keys_str_mv | AT jinshanfeng strategiesforpreventingendoscopicrecurrenceofcrohnsdisease1yearaftersurgeryanetworkmetaanalysis AT jinyuli strategiesforpreventingendoscopicrecurrenceofcrohnsdisease1yearaftersurgeryanetworkmetaanalysis AT xiuyanchen strategiesforpreventingendoscopicrecurrenceofcrohnsdisease1yearaftersurgeryanetworkmetaanalysis AT zhengyang strategiesforpreventingendoscopicrecurrenceofcrohnsdisease1yearaftersurgeryanetworkmetaanalysis AT shanghaili strategiesforpreventingendoscopicrecurrenceofcrohnsdisease1yearaftersurgeryanetworkmetaanalysis |